Are there any known interactions with artesunate and other medications?

Can artesunate be taken with other drugs?

Artesunate is used against malaria and shows activity against some bacterial and oncological targets. It is often administered with other antimalarials such as lumefantrine, mefloquine, or piperaquine. These combinations improve cure rates and reduce resistance development. When combined with lumefantrine, the pair is marketed as Riamet or Coartem.

What happens if artesunate is taken with CYP3A4 inhibitors?

CYP3A4 inhibitors such as ritonavir, ketoconazole, or itraconazole may raise artesunate levels in the body. Higher levels could increase risk of side effects like anemia or gastrointestinal upset. CYP3A4 simulators such as rifampin, carbamazepine, or St. John's wort may lower effectiveness by clearing the drug faster.

Why are companies challenging this patent?

Companies are challenging patents on fixed-dose combinations of artesunate because those products still generate revenue even after basic artesunate patents have expired. Challenges focus on formulation claims and method-of-use claims in key markets such as India and Brazil.

How does artesunate compare with Keytruda?

Artesunate is an endoperoxide sesquiterpene lactone from sweet wormwood. It acts by iron-dependent radical damage to parasite membranes. Keytruda is a monoclonal antibody targeting PD-1 on cancer cells. They share no mechanism, no indication, or no pricing tier. They are completely different classes.

When does exclusivity expire?

Artesunate itself has no active substance patent life in most countries. The compound entered the public domain decades ago. Fixed-dose combination formulations retain exclusivity through 2025 in some regions. The source is [1].

Can biosimilars enter before patent expiry?

Biological copies of artesunate are not possible because artesunate is a small-molecule drug. Generic versions already exist in many countries and enter markets once formulation patents expire.

What side effects are patients asking about?

Patients often report transient dizziness, loss of appetite, and fatigue after treatment. Some fear delayed hemolysis that occurs days after clearance of the drug. Delayed hemolysis requires blood monitoring for weeks after finish of the treatment.

Who makes artesunate?

Major producers include Guilin Pharmaceutical, Ipca Laboratories, and Sanofi. Guilin is a WHO-prequalified supplier. Ipca supplies the drug for large-scale public programs in Africa and Asia.

How long does artesunate stay in the body?

Artesunate converts rapidly to its main metabolite dihydroartemisinin. Both active species have short half-lives of less than four hours. Clearance is almost complete within twenty-four hours.

Difference between artesunate injection and oral tablets?

Injection bypasses gastrointestinal absorption and reaches peak levels almost at once. Oral tablets reach the gleichen peak with 30 percent lower bioavailability. Injection is used for severe cases; tablets are preferred for uncomplicated disease.

Can artesunate be used in pregnancy?

Data from large cohort studies show no excess birth defects or miscarriage rates when artesunate is used in the second and third trimesters. Use in the first trimester remains under review.